Abstract:The viral macrophage inflammatory protein II (vMIP-II) shows a broad spectrum interaction with both CC and CXC chemokine receptors including CCR5 and CXCR4, two principal coreceptors for the cellular entry of human immunodeficiency virus type 1 (HIV-1). Recently, we have shown that a synthetic peptide derived from the N-terminus of vMIP-II, designated as V1, is a potent antagonist of CXCR4 but not CCR5 [Zhou, N., et al. (2000) Biochemistry 39, 3782-3787]. In this study, we synthesized a series of new peptides derived from other regions of vMIP-II and characterized their binding activities with both CXCR4 and CCR5. The results provided further support for the notion that the N-terminus of vMIP-II is the major determinant for CXCR4 recognition and that vMIP-II probably interacts with other chemokine receptors such as CCR5 with different sequence and conformational determinants. To understand the structure-function relationship of V1 peptide, its solution conformation was studied using circular dichroism spectroscopy, which showed a random conformation similar to that of the corresponding N-terminus in native vMIP-II. In addition, we synthesized a series of mutant analogues of V1 containing alanine, glycine, or phenylalanine substitution at various positions. Residues Val-1, Arg-7, and Lys-9 of V1 peptide were found to be critical for receptor interaction, because single alanine replacement at these positions dramatically decreased peptide binding to CXCR4. In contrast, alanine or phenylalanine substitution at Cys-11 led to significant enhancement in peptide affinity for CXCR4. Finally, we showed that V1 peptide inhibits HIV-1 replication in CXCR4(+) T-cell lines. These studies provide new insights into the structure-function relationship of V1 peptide and demonstrate that this peptide may be a lead for the development of therapeutic agents.

A Virion-Specific Inhibitory Molecule with Therapeutic Potential for Human-Immunodeficiency-Virus Type-1

SAMHD1:a new HIV-1 inhibitory factor

HIV-2 Vpx neutralizes host restriction factor SAMHD1 to promote viral pathogenesis

Design of Vif-Derived Peptide Inhibitors with Anti-HIV-1 Activity by Interrupting Vif-CBFβ Interaction

Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry Into Cells

Inhibition of Hiv Replication: A Powerful Antiviral Strategy by Ifn-Beta Gene Delivery in Cd4(+) Cells

HIV-1 Gp41-Targeting Fusion Inhibitory Peptides Enhance the Gp120-Targeting Protein-Mediated Inactivation of HIV-1 Virions

Peptide Inhibitors of Hiv-1 Virus Infection Based on Cullin-5

Structure-Function Study and Anti-Hiv Activity of Synthetic Peptide Analogues Derived from Viral Chemokine Vmip-Ii

An Artificial Peptide-Based Bifunctional HIV-1 Entry Inhibitor That Interferes with Viral Glycoprotein-41 Six-Helix Bundle Formation and Antagonizes CCR5 on the Host Cell Membrane

A Novel Peptide Antagonist of CXCR4 Derived from the N-Terminus of Viral Chemokine Vmip-Ii

Zinc finger protein designed to target 2-long terminal repeat junctions interferes with human immunodeficiency virus integration

Construction of a High Efficient Retrovirus Vector Psiv-1 and Its Preliminary Identification of Functions

Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.

A heterocyclic compound inhibits viral release by inducing cell surface BST2/Tetherin/CD317/HM1.24

A Novel Therapeutic Vaccination Delays Cart-Resistant Hiv-1 Reservoir Rebound in Hiv-1 Infected Humanized Mice

Dominant Negative Mutants of Human Immunodeficiency Virus Type 1 Viral Infectivity Factor (Vif) Disrupt Core-Binding Factor Beta-Vif Interaction

Design of the artificial N-peptides with coiled-coil trimer structure against HIV-1 based on the SWISS MODEL and HDOCK-aided strategy

Design, synthesis, and biological evaluation of 2-amino-N-(2-methoxyphenyl)-6-((4-nitrophenyl)sulfonyl)benzamide derivatives as potent HIV-1 Vif inhibitors.

Short Communication: Efficiently Inhibiting HIV-1 Replication by a Prototype Foamy Virus Vector Expressing Novel H1 Promoter-Driven Short Hairpin RNAs

[Progress in the Study of HIV-1 Vif and Related Inhibitors].